QT Assessment in Early Clinical Development Can the Predictive Value be Enhanced to be Similar to That of a TQT study?

Posted:
15
January 2012

Following the JCP Nov 2011 publication proposing food as a viable means for demonstrating assay sensitivity for ECG assessment in clinical trials, this is now proposed alongside other potential methods at the upcoming CSRC ThinkTank meeting on QT Assessment in Early Clinical Development being held 2 Feb at the FDA Headquarters in Silver Spring.The purpose of these meetings is the formation of collaborative CSRC research groups with members from regulators, sponsors and academia with the goal to perform, promote and compile research in areas addressing identified key knowledge gaps.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more